Oncolytic virus-based combination therapy in breast cancer
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved..
Breast cancer continues to pose significant challenges in the field of oncology, necessitating innovative treatment approaches. Among these, oncolytic viruses have emerged as a promising frontier in the battle against various types of cancer, including breast cancer. These viruses, often genetically modified, have the unique ability to selectively infect and destroy cancer cells while leaving healthy cells unharmed. Their efficacy in tumor eradication is not only owing to direct cell lysis but also relies on their capacity to activate the immune system, thereby eliciting a potent and sustained antitumor response. While oncolytic viruses represent a significant advancement in cancer treatment, the complexity and adaptability inherent to cancer require a diverse array of therapies. The concept of combining oncolytic viruses with other treatment modalities, such as chemotherapy, immunotherapy, and targeted therapies, has received significant attention. This synergistic approach capitalizes on the strengths of each therapy, thus creating a comprehensive strategy to tackle the heterogeneous and evolving nature of breast cancer. The purpose of this review is to provide an in-depth discussion of preclinical and clinical viro-based combination therapy in the context of breast cancer.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:585 |
---|---|
Enthalten in: |
Cancer letters - 585(2024) vom: 31. März, Seite 216634 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Bahreyni, Amirhossein [VerfasserIn] |
---|
Links: |
---|
Themen: |
Breast cancer |
---|
Anmerkungen: |
Date Completed 05.03.2024 Date Revised 05.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.canlet.2024.216634 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM367990954 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM367990954 | ||
003 | DE-627 | ||
005 | 20240305232310.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240204s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.canlet.2024.216634 |2 doi | |
028 | 5 | 2 | |a pubmed24n1317.xml |
035 | |a (DE-627)NLM367990954 | ||
035 | |a (NLM)38309616 | ||
035 | |a (PII)S0304-3835(24)00028-4 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Bahreyni, Amirhossein |e verfasserin |4 aut | |
245 | 1 | 0 | |a Oncolytic virus-based combination therapy in breast cancer |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 05.03.2024 | ||
500 | |a Date Revised 05.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. | ||
520 | |a Breast cancer continues to pose significant challenges in the field of oncology, necessitating innovative treatment approaches. Among these, oncolytic viruses have emerged as a promising frontier in the battle against various types of cancer, including breast cancer. These viruses, often genetically modified, have the unique ability to selectively infect and destroy cancer cells while leaving healthy cells unharmed. Their efficacy in tumor eradication is not only owing to direct cell lysis but also relies on their capacity to activate the immune system, thereby eliciting a potent and sustained antitumor response. While oncolytic viruses represent a significant advancement in cancer treatment, the complexity and adaptability inherent to cancer require a diverse array of therapies. The concept of combining oncolytic viruses with other treatment modalities, such as chemotherapy, immunotherapy, and targeted therapies, has received significant attention. This synergistic approach capitalizes on the strengths of each therapy, thus creating a comprehensive strategy to tackle the heterogeneous and evolving nature of breast cancer. The purpose of this review is to provide an in-depth discussion of preclinical and clinical viro-based combination therapy in the context of breast cancer | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Breast cancer | |
650 | 4 | |a Cancer immunotherapy | |
650 | 4 | |a Combination therapy | |
650 | 4 | |a Oncolytic virus | |
700 | 1 | |a Mohamud, Yasir |e verfasserin |4 aut | |
700 | 1 | |a Luo, Honglin |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer letters |d 1976 |g 585(2024) vom: 31. März, Seite 216634 |w (DE-627)NLM000147273 |x 1872-7980 |7 nnns |
773 | 1 | 8 | |g volume:585 |g year:2024 |g day:31 |g month:03 |g pages:216634 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canlet.2024.216634 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 585 |j 2024 |b 31 |c 03 |h 216634 |